| Febrile Neutropenia
Neulasta vs Nyvepria
Side-by-side clinical, coverage, and cost comparison for febrile neutropenia.Deep comparison between: Neulasta vs Nyvepria with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsNyvepria has a higher rate of injection site reactions vs Neulasta based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Nyvepria but not Neulasta, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Neulasta
Nyvepria
At A Glance
SC injection
Once per chemotherapy cycle
G-CSF (colony-stimulating factor)
SC injection
Once per chemotherapy cycle
Colony-stimulating factor (G-CSF)
Indications
- Febrile Neutropenia
- Hematopoietic subsyndrome of acute radiation syndrome
- Febrile Neutropenia
Dosing
Febrile Neutropenia 6 mg SC once per chemotherapy cycle for adults and pediatric patients >=45 kg; weight-based dosing (1.5-4 mg SC) for pediatric patients weighing 10-44 kg; 0.1 mg/kg for those <10 kg. Do not administer between 14 days before and 24 hours after chemotherapy.
Hematopoietic Subsyndrome of Acute Radiation Syndrome Two doses of 6 mg each SC one week apart for adults and pediatric patients >=45 kg; weight-based dosing for pediatric patients <45 kg. Administer first dose as soon as possible after suspected or confirmed exposure to radiation >2 Gy, and second dose one week after.
Febrile Neutropenia 6 mg SC injection once per chemotherapy cycle; do not administer between 14 days before and 24 hours after cytotoxic chemotherapy; weight-based dosing for pediatric patients weighing less than 45 kg.
Contraindications
- History of serious hypersensitivity reaction to pegfilgrastim or filgrastim, including anaphylaxis
- History of serious allergic reactions to pegfilgrastim products or filgrastim products, including anaphylaxis
Adverse Reactions
Most common (>=5%) Bone pain, pain in extremity
Serious Splenic rupture, acute respiratory distress syndrome, serious hypersensitivity reactions, sickle cell crisis, glomerulonephritis, leukocytosis, thrombocytopenia, capillary leak syndrome, myelodysplastic syndrome, acute myeloid leukemia, aortitis
Postmarketing Splenic rupture, splenomegaly, ARDS, anaphylaxis, skin rash, urticaria, sickle cell crisis, glomerulonephritis, leukocytosis, thrombocytopenia, capillary leak syndrome, injection site reactions, Sweet's syndrome, cutaneous vasculitis, MDS, AML, aortitis, alveolar hemorrhage
Most common (>=5%) bone pain, pain in extremity
Serious splenic rupture, acute respiratory distress syndrome, serious allergic reactions, sickle cell disorders, glomerulonephritis, leukocytosis, thrombocytopenia, capillary leak syndrome, myelodysplastic syndrome, acute myeloid leukemia, aortitis
Postmarketing splenic rupture, splenomegaly, ARDS, allergic reactions/hypersensitivity (anaphylaxis, skin rash, urticaria, generalized erythema, flushing), sickle cell crisis, glomerulonephritis, leukocytosis, thrombocytopenia, capillary leak syndrome, injection site reactions, Sweet's syndrome, cutaneous vasculitis, MDS, AML, aortitis, alveolar hemorrhage
Pharmacology
Pegfilgrastim is a PEGylated G-CSF analogue (colony-stimulating factor) that binds specific cell surface receptors on hematopoietic cells, stimulating proliferation, differentiation, commitment, and functional activation; clearance is neutrophil receptor-mediated and nonlinear with dose.
Pegfilgrastim-apgf is a PEGylated recombinant human G-CSF that binds specific cell surface receptors on hematopoietic cells, stimulating proliferation, differentiation, commitment, and end cell functional activation.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Neulasta
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (1/12) · Qty limit (11/12)
Nyvepria
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (9/12)
UnitedHealthcare
Neulasta
- Covered on 4 commercial plans
- PA (2/8) · Step Therapy (0/8) · Qty limit (0/8)
Nyvepria
- Covered on 4 commercial plans
- PA (1/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Neulasta
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Nyvepria
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableCancerCare: Chemotherapy Induced Neutropenia
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableCancerCare: Chemotherapy Induced Neutropenia
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
NeulastaView full Neulasta profile
NyvepriaView full Nyvepria profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.